爱德华兹生命科学(EDWARDS):1季度符合预期 二尖瓣置换步入商业化阶段_业绩回顾

中金公司
Yesterday

1Q25 业绩符合我们预期公司公布2025 年1 季度业绩:剔除剥离业务后,收入14.13 亿美元,同比+6.2%;经调整EPS 为0.64 美元,2024 年1 季度同口径为0.55 美元。1Q25 业绩符合我们的预期。发展趋势TAVR 业务表现稳健。1 季度TAVR 收入10.5 亿美元,同比+3.8%。公司表示美国市场和非美市场增速相似。在美国市场,公司的 SAPIEN 3 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10